{
    "2019-10-29": [
        [
            {
                "time": "2019-11-08",
                "original_text": "复星医药(02196)11月8日将有1亿股非公开发行A股限售股上市流通 解禁",
                "features": {
                    "keywords": [
                        "复星医药",
                        "限售股",
                        "解禁",
                        "非公开发行"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-10-29",
                "original_text": "复星医药：前三季净利润同比下降1.45% 盈利能力下降",
                "features": {
                    "keywords": [
                        "复星医药",
                        "净利润",
                        "同比下降",
                        "盈利能力"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-10-29",
                "original_text": "复星医药：前三季度扣非净利润增长8.21%至17.22亿元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "扣非净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-10-29",
                "original_text": "【民生医药|季报点评】复星医药：现金流持续上升，创新药上市有望带动利润率回升",
                "features": {
                    "keywords": [
                        "复星医药",
                        "现金流",
                        "上升",
                        "创新药",
                        "利润率"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-10-29",
                "original_text": "复星医药旗下公司 召回5万支注射剂 产品问题",
                "features": {
                    "keywords": [
                        "复星医药",
                        "召回",
                        "注射剂",
                        "产品问题"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}